EUVIMEDSkopri EUVIMED
Crossref

Toosendanin Induces Cell Cycle Arrest and Apoptosis to Suppress Diffuse Large B‐Cell Lymphoma Growth by Inhibiting PI3Kα /β and PLK1 Signaling

Qian Hu, Mengyao Wang, Meng Chen, Jinjin Wang, Ting Niu iD

Phytotherapy Research · 2025-05 · 39 (5) · 1930-1945

DOI: 10.1002/ptr.8439 ↗

At a glance

Journal article in Phytotherapy Research, published online on 2025-02-13. Written by Qian Hu and 4 co-authors. Institution: Department of Hematology, West China Hospital, Sichuan University, Chengdu, China. Major MEDLINE topics: Lymphoma, Large B-Cell, Diffuse, Protein Serine-Threonine Kinases, Apoptosis, Cell Cycle Checkpoints. Cited 5 times so far (Crossref); 52 references. Funded by: National Natural Science Foundation of China, Sichuan University Postdoctoral Interdisciplinary Innovation Fund, 1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Diffuse large B‐cell lymphoma (DLBCL) is an aggressive and heterogeneous subtype of non‐Hodgkin lymphoma, with two‐thirds of patients relapsing or resisting existing therapies, highlighting the urgent need for effective treatments. Toosendanin (TSN), a triterpenoid from Meliae Cortex, exhibits significant anti‐cancer activity by modulating cell survival and proliferation. This study investigates the anti‐lymphoma effects and underlying mechanisms of TSN, proposing it as a potential therapeutic agent to address the challenges of DLBCL. Network pharmacology, molecular docking, and transcriptome sequencing were employed to predict TSN's anti‐DLBCL potential. Findings were validated through in vitro and in vivo experiments, including cell viability assays, flow cytometry, quantitative PCR, Western blotting, reverse experiments with small‐molecule inhibitors or genetic editing, and a cell‐derived xenograft (CDX) model. Bioinformatics analyses revealed TSN's strong binding affinity to PI3Kα/β and Polo‐like kinase 1 (PLK1). Experiments showed that TSN downregulated the PI3K/Akt signaling pathway and reduced PLK1 mRNA and protein levels, inducing apoptosis, cell cycle arrest, and cell death in DLBCL cells. RNA sequencing and metabolic assays indicated TSN upregulated cholesterol biosynthesis in DLBCL cells. Co‐treatment with a statin enhanced TSN's anti‐DLBCL effects while mitigating hepatic and pulmonary toxicity. This study identifies TSN as a dual inhibitor of PI3K and PLK1 with significant therapeutic potential for DLBCL. It also proposes a lipid‐modulating strategy to enhance TSN's cytotoxicity while reducing adverse effects, offering a promising approach to improve DLBCL treatment outcomes.

Subjects

MeSH terms (MEDLINE)

Lymphoma, Large B-Cell, DiffuseProtein Serine-Threonine KinasesApoptosisCell Cycle CheckpointsCell Cycle ProteinsProto-Oncogene ProteinsDrugs, Chinese HerbalAntineoplastic Agents, PhytogenicHumansSignal TransductionAnimalsPolo-Like Kinase 1Cell Line, TumorPhosphatidylinositol 3-KinasesMiceMolecular Docking SimulationXenograft Model Antitumor AssaysCell ProliferationTriterpenes

Author keywords

Toosendanincholesterol metabolismdiffuse large B‐cell lymphomaphosphatidylinositol 3‐kinasepolo‐like kinase 1traditional Chinese medicine

Substances

Protein Serine-Threonine KinasesCell Cycle ProteinsPolo-Like Kinase 1Phosphatidylinositol 3-KinasestoosendaninProto-Oncogene ProteinsDrugs, Chinese HerbalAntineoplastic Agents, PhytogenicTriterpenes

Authors and institutions

  • Department of Hematology, West China Hospital, Sichuan University, Chengdu, China.
  • State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
  • National Facility for Translational Medicine (Sichuan), West China Hospital, Sichuan University, Chengdu, China.
  • West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, China.

ORCID profiles: Ting Niu

Funding

  • National Natural Science Foundation of China
  • Sichuan University Postdoctoral Interdisciplinary Innovation Fund
  • 1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University
  • Translational Research Grant of NCRCH
  • China Postdoctoral Science Foundation
  • Chengdu Municipal Science and Technology Program
  • Key Research and Development Program of Sichuan Province
  • National Key Research and Development Program of China

Cite

APA

Hu, Q., Wang, M., Chen, M., Wang, J., & Niu, T. (2025). Toosendanin Induces Cell Cycle Arrest and Apoptosis to Suppress Diffuse Large B‐Cell Lymphoma Growth by Inhibiting PI3Kα /β and PLK1 Signaling. Phytotherapy Research, 39(5), 1930-1945. https://doi.org/10.1002/ptr.8439

Vancouver

Hu Q, Wang M, Chen M, Wang J, Niu T. Toosendanin Induces Cell Cycle Arrest and Apoptosis to Suppress Diffuse Large B‐Cell Lymphoma Growth by Inhibiting PI3Kα /β and PLK1 Signaling. Phytotherapy Research. 2025;39(5):1930-1945. doi:10.1002/ptr.8439

BibTeX
@article{Hu2025,
  author = {Hu, Qian and Wang, Mengyao and Chen, Meng and Wang, Jinjin and Niu, Ting},
  title = {Toosendanin Induces Cell Cycle Arrest and Apoptosis to Suppress Diffuse Large B‐Cell Lymphoma Growth by Inhibiting PI3Kα /β and PLK1 Signaling},
  journal = {Phytotherapy Research},
  year = {2025},
  volume = {39},
  number = {5},
  pages = {1930--1945},
  doi = {10.1002/ptr.8439}
}
Start for free →